Neuroimaging-based biomarkers for treatment selection in major depressive disorder
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
The use of neuroimaging approaches to identify likely treatment outcomes in patients with major depressive disorder is developing rapidly. Emerging work suggests that resting state pretreatment metabolic activity in the fronto-insular cortex may distinguish between patients likely to respond to psychotherapy or medication and may function as a treatment-selection biomarker. In contrast, high metabolic activity in the subgenual anterior cingulate cortex may be predictive of poor outcomes to both medication and psychotherapy, suggesting that nonstandard treatments may be pursued earlier in the treatment course. Although these findings will require replication before clinical adoption, they provide preliminary support for the concept that brain states can be measured and applied to the selection of a specific treatment most likely to be beneficial for an individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. (A) Scatterplot of pretreatment 2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (PET) metabolic activity in the anterior insular cortex of individual patients remitting (REM) and not responding (NR) to treatment with either escitalopram or cognitive behavioral therapy (CBT). Normalized metabolic activity in the anterior insula subdivided patients into hypermetabolic and hypometabolic subgroups. (B) Insula activity correlated with changes in the Hamilton Depression Rating Scale (HDRS) score in the full cohort of subjects treated with either CBT or escitalopram oxalate. From reference 28: McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013:70:821-829.](https://figures.cochat.ai/paper-figures/bd1421e1d2db48ffab7da8c8c16b961d/neuroimaging-based-biomarkers-for-treatment-selection-in-major-depressive-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“this region is thought to play a central role in the pathophysiology of MDD (Dunlop & Mayberg, 2014).”
From A novel resting-state functional magnetic resonance imaging signature of resilience to recurrent depression (2017) · cites this paper as Dunlop & Mayberg, 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Dissociable intrinsic connectivity networks for salience processing and executive control
Seeley, W. W., Menon, V., Schatzberg, A. F., Keller, J., Glover, G. H., Kenna, H., Reiss, A. L., & Greicius, M. D. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5587-06.2007 · Cited by 7,426
Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
Fox, M. D., & Raichle, M. E. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2201 · Cited by 6,700
How do you feel — now? The anterior insula and human awareness
(Bud) Craig, A. D. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2555 · Cited by 6,657 · cited 1×
“64 Thus, of the structural imaging predictors, reduced hippocampal volume may serve as a nonspecific predictor of a poor treatment outcome, but the data, to date, do”
BackgroundSaliency, switching, attention and control: a network model of insula function
Menon, V., & Uddin, L. Q. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0262-0 · Cited by 5,592
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 2×
“…group-level continuous outcomes, such as overall mean change or percent improvement) are the most appropriate outcome metric for TSB studies because the individual is the unit of analysis, although more sophisticated determine a trajectory of change for each individual patient may allow for…”
BackgroundSelf-citationInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“Most recently, the pathophysiologic role of inflammation has been recognized as a potential 13 or other predictors of treatment outcomes.”
BackgroundSridharan, D., Levitin, D. J., & Menon, V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800005105 · Cited by 2,892
Research works printed but not linked: 7
- Uher R., Am J Psychiatry. 2014 Jul 14. Epub ahead of print.
- Fu CH., 2012, Neurobiol Dis., 52, 75
- American Psychiatric Association., Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
- Konarski JZ., 2009, J Psychiatry Neurosci., 34, 175
- Dunlop BW., J Neuropsychiatry Clin Neurosci. 2014. In press.
- Samson AC., 2011, J Psychiatr Res., 35, 1214
- Frodl T., 2008, J Psychiatry Neurosci., 33, 423
Cited by
Lactate in the brain: from metabolic end-product to signalling molecule
Magistretti, P. J., & Allaman, I. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.19 · Cited by 1,298
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Overactivity in the sgACC is a replicated pathological feature ofmajor depressive disorder, and reduction of activity in the sgACC is associatedwith response to conventional antidepressant treatments (31, 33).”
ResultPrecision psychiatry: a neural circuit taxonomy for depression and anxiety
Williams, L. M. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00579-9 · Cited by 641
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Dunlop, B. W., Rajendra, J. K., Craighead, W. E., Kelley, M. E., McGrath, C. L., Choi, K. S., Kinkead, B., Nemeroff, C. B., & Mayberg, H. S. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050518 · Cited by 342
“We have previously proposed that psychotherapy-responsive depression may represent a brain state with sufficiently adequate connectivity in mood-regulating systems such that engagement of these systems via psychotherapy can reduce negative emotional states (25).”
Self-citation
Metadata
- Authors
- Dunlop, B. W., & Mayberg, H. S.
- Affiliations
- Emory University (US)
- Corresponding author
- Dunlop, Boadie W.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2014-12-31
- Volume
- 16
- Issue
- 4
- Pages
- 479-490
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC4336918
- OpenAlex
- W202043522
- Cited by
- 127
- References
- 75
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 9 · 2020: 15 · 2019: 12 · 2018: 14 · 2017: 16 · 2016: 15 · 2015: 5
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH073719)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- major depressive disorder, treatment selection, neuroimaging biomarkers, subgenual anterior cingulate cortex, treatment response prediction, psychotherapy, antidepressants, personalized treatment
- MeSH terms
- Antidepressive Agents, Brain, Depressive Disorder, Major, Major Depressive Disorder, Humans, Biomarkers, Precision Medicine, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroimaging-based biomarkers for treatment selection in major depressive disorder. https://app.cochat.ai/papers/10.31887/dcns.2014.16.4/bdunlop
- The paper
- Dunlop, B. W., & Mayberg, H. S. (2014). Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2014.16.4/bdunlop
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.